Floatz logo

2x-121

B-cell Malignancy, Low-grade

Eisai LimitedPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the B-cell Malignancy, Low-grade cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Fox Chase Cancer Center
Phase 3BB
Pembrolizumab
University of Washington
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
German High-Grade Non-Hodgkin's Lymphoma Study Group
Phase 3BB

View all 50 →

Same molecule, other indications

2x-121 is also rated in:

ovarian cancerDormant
BB
Indicative ·
64 / 100
View asset →
breast cancerDormant
BB
Indicative ·
64 / 100
View asset →
cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →